associated with delay in giving appropriate therapy, increased mortality, and high risk of infection recurrence [7] [8] [9] . Several studies, mainly limited to single centers or countries, describe rates and risk factors for specific resistant pathogens, such as extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae or multidrug-resistant (MDR) bacteria in patients with cancer and HSCT recipients [10] [11] [12] [13] . The majority, however, were performed in countries with high resistance rates in both the hospitalized and general populations [12] [13] [14] . The risk of infection is influenced by local factors, among them prevalence of resistance, prophylactic practices, empiric treatment, and antimicrobial stewardship. Only a handful of studies focus on children and autologous HSCT (auto-HSCT) patients [12, 15, 16] . This study aimed to describe resistance rates and risk factors in GNR bacteremia in HSCT patients, based on large intercontinental data.
METHODS

Study Design and Data Collection
This was a noninterventional prospective study. All patients in whom allogeneic HSCT (allo-HSCT) or auto-HSCT was performed during February 2014-May 2015 in the participating centers were included. Data on GNR bacteremia episodes that occurred from the initiation of the conditioning regimen until 6 months after the HSCT were reported, including pathogen and its antimicrobial susceptibility, presence of risk factors, and mortality. This study was performed in accordance with the appropriate regulations in the participating countries including approval by the ethical committees as required, and registered at ClinicalTrials.gov (NCT02257931).
The primary endpoint was to determine the proportion of GNRs resistant to (1) one of noncarbapenem anti-Pseudomonas β-lactams (noncarbapenems), including ceftazidime or cefepime or β-lactam/β-lactamase inhibitors (βL/βLIs); (2) carbapenems (one of meropenem/imipenem/doripenem); (3) one of fluoroquinolones; (4) MDR pathogens.
The secondary endpoints were to determine (1) proportion of GNRs resistant to other antibiotics; and (2) risk factors for resistant GNRs, as defined in the primary endpoints.
Microbiological Workup
Guidelines used to determine isolates' susceptibility were by the European Committee for Antimicrobial Susceptibility Testing in 41 (64.1%) laboratories, the Clinical and Laboratory Standards Institute in 19 (29.7%) laboratories, and others in 4 (6.2%) laboratories. Resistance to antibiotics was studied by in vitro sensitivity tests in the local laboratories using disk diffusion in 46 of 64 (71.9%) and/or minimum inhibitory concentration determination in 60 of 64 (93.8%) centers. Pathogens with intermediate susceptibility to antibiotics were considered resistant.
Definitions
An MDR GNR was defined as bacteria resistant to ≥1 agent in ≥3 of the following categories: (1) broad-spectrum cephalosporins (ceftazidime or cefepime); (2) anti-Pseudomonas βL/ βLIs; (3) carbapenems; (4) aminoglycosides; (5) fluoroquinolones. All Stenotrophomonas maltophilia strains were considered MDR. Extensively drug-resistant (XDR) bacteria defined if checked for susceptibility to all relevant antimicrobials and found nonsusceptible to ≥1 agent in all but ≤2 categories [17] . Infections occurring >48 hours since the hospitalization were considered hospital acquired.
Neutropenia was defined as an absolute neutrophil count <500 cells/μL.
Breakthrough bacteremia was defined as bacteremia developing during antibiotic treatment (including fluoroquinolone prophylaxis) provided for ≥48 hours before obtaining the blood culture.
Geographic regions [4] included Northwest (Austria, Belgium, Denmark, Finland, France, Germany, Netherlands, Sweden, Switzerland, United Kingdom); Southeast (Croatia, Cyprus, Czech Republic, Greece, Israel, Italy, Lithuania, Poland, Portugal, Russia, Slovakia, Spain, Turkey); other countries (Australia, China).
Statistical Analysis
The main characteristics of patients were reported by descriptive statistics on the total of the available information.
The incidence of resistance was computed as a percentage, the denominator being the number of GNR pathogens and the numerator being the number of pathogens classified as "resistant. " Early mortality was computed as a percentage of death occurred within 7 days after bacteremia on the episodes with a follow-up available at the same time.
The relationship between resistance and the following risk factors was investigated:
• Background: sex, age at HSCT, underlying disease, myeloablative conditioning, fluoroquinolone prophylaxis.
• At the time of bacteremia: time since HSCT, duration of neutropenia, neutrophil recovery, duration of hospitalization, hospital-acquired infection, breakthrough bacteremia, graftvs-host disease (GVHD), acute GVHD grade II-IV, venoocclusive disease.
• Before bacteremia, within 1 month: urinary catheter, ≥2 weeks of steroids, and/or other immunosuppressive treatment; within 3 months: any hospitalization, hospitalization in the intensive care unit (ICU), any bacteremia, previous antibiotic therapy, and number of antibiotic classes.
Differences between groups were tested using linear or logistic regression models, using the generalized estimating equation method to take into account the dependence of observations nested by patient and center [18] . The same models were used to study all relationships between resistance and characteristics or prognostic factors. Variables showing significance from the univariate model entered a multivariable model. The results obtained from these analyses are considered as exploratory and hypothesis-generating. A P value <.05 was considered statistically significant. All P values are 2 sided. All the analyses were performed using the statistical software SAS version 9.4 (SAS Institute, Cary, North Carolina).
RESULTS
Patients and Episodes
Sixty-five HSCT centers from 25 countries reported data on 655 GNR episodes in 591 patients ( 
Resistance Rates
Half of GNRs were resistant to fluoroquinolones and to noncarbapenems, 18.5% were carbapenem resistant, and 35.2% were MDR ( Table 3) . One of 73 (1.4%) Pseudomonas aeruginosa and 4 of 14 (28.6%) Acinetobacter species were XDR. Resistance rates to other antibiotics are presented in Table 3 .
There was no strong correlation between the rates of GNR bacteremia and resistance to noncarbapenems and carbapenems per country; and no correlation between fluoroquinolone resistance and bacteremia rate per center (Supplementary Figure 1A-C) .
Resistance Rates According to Pathogens
Fluoroquinolone resistance was significantly more frequent among Enterobacteriaceae (57.2% vs 30.7%; P < .0001); carbapenem resistance (50.9% vs 8.4%; P < .0001), and multidrug resistance (46.6% vs 31.9%; P = .001) in nonfermentative rods (Table 4) .
Six of 31 (19%) S. maltophilia isolates were resistant to trimethoprim-sulfamethoxazole.
One-third of noncarbapenem-resistant, and half of MDR pathogens, were carbapenem resistant (Supplementary Table 2 vs 8.9%), and multidrug resistance (43.7% vs 20.2%) were higher in GNRs isolated in allo-HSCT vs auto-HSCT recipients (P < .001 for all) ( Tables  4 and 5 ).
Resistance Rate in Children Versus Adults
Similar resistance rates were observed in children and adults. Only the resistance rate to fluoroquinolones and βL/βLIs was significantly higher in adults compared with children following allo-HSCT (P < .0001 and P = .048, respectively) (Table 3) ; the difference was significant in southeast countries only.
Geographical Distribution of Resistance Rates
There was a wide distribution in the resistance rates between countries (Supplementary 
Risk Factors for Resistance
Univariate analysis of risk factors for resistant GNRs in allo-HSCT and auto-HSCT recipients is presented in Supplementary  Tables 4 and 5 . Multivariable analysis was possible in allo-HSCT patients only (Table 5) , as rate of resistance was low in auto-HSCT patients.
To study the association between fluoroquinolone prophylaxis and resistance, we compared resistance rates in GNRs cultured during the period when prophylaxis is provided (in neutropenic patients without empiric or targeted antibiotics therapy), in centers that do and do not provide prophylaxis.
The rate of fluoroquinolone-resistant GNRs was higher in centers providing prophylaxis (79% vs 50%, P = .001 in allo-HSCT; 74% vs 25%, P < .001 in auto-HSCT). The rate of noncarbapenem-resistant (36% vs 13%; P = .002) and MDR (35% vs 8%; P < .001) bacteria was higher in auto-HSCT patients in centers providing prophylaxis (Supplementary Table 7 ).
Outcome
The 7-day mortality was 38 of 589 (6.5%). The mortality according to resistance pattern was 9% vs 2% (P = .002) in episodes caused by noncarbapenem resistant vs sensitive GNRs; 18% vs 4% (P < .001) in those carbapenem resistant vs sensitive; and 11% vs 4% (P = .002) in MDR vs non-MDR. 
DISCUSSION
In this study, we demonstrate antimicrobial susceptibility patterns among GNRs causing bacteremia in HSCT patients, and geographical distribution of resistance in 25 countries from Europe, Asia, and Australia. We compare allo-and auto-HSCT recipients, and children and adults; and analyze risk factors for antibiotic resistance.
The emerging resistance challenges antibacterial prophylaxis policy and complicates empiric and targeted treatment choices. Benefit of fluoroquinolone prophylaxis was demonstrated in a country with a baseline resistance of approximately 20% . The following differences were significant: the resistance rates to fluoroquinolones, noncarbapenems, carbapenems, and multidrug resistance were significantly higher in GNRs isolated in allogeneic HSCT vs autologous HSCT recipients (*P < .001 for all). The rate of resistance to fluoroquinolones and anti-Pseudomonas βL/βLIs was significantly higher in adults vs children following allogeneic HSCT (**P < .0001 and ***P = .048, respectively).
Abbreviations: allo, allogeneic; auto, autologous; βL/βLI, β-lactam/β-lactamase inhibitor; GNR, gram-negative rod; HSCT, hematopoietic stem cell transplantation. Significant differences between Enterobacteriaceae and nonfermentative rods (P = .001).
in GNRs from the community and medical departments [19, 20] . In our study, 39% of GNRs causing community-acquired infections in allo-HSCT and 63% in auto-HSCT were fluoroquinolone resistant (Supplementary Tables 4 and 5 ). High rates of fluoroquinolone resistance may be the price to pay for lower rates of bacteremia in centers providing prophylaxis. We could not, however, demonstrate correlation between the rates of bacteremia and fluoroquinolone resistance (Supplementary Figure 1A) . Doubts regarding the benefits of fluoroquinolone prophylaxis are accompanied by concern about increased rates of resistance to other antibiotics following exposure to fluoroquinolones. No association between fluoroquinolone prophylaxis and the increase in MDR bacteria was shown in the meta-analysis of studies published up to 2005 [21] . Later published studies, however, correlated exposure to fluoroquinolones with increase in infections resulting from fluoroquinolone-resistant, ESBL-producing, carbapenem-resistant, and MDR pathogens [14, 22, 23] . In our study, in auto-HSCT patients, treatment in centers providing fluoroquinolone prophylaxis, breakthrough on fluoroquinolones, and previous exposure to fluoroquinolones (Supplementary Tables 5 and 7) were associated with resistance to noncarbapenems and MDR. The risk could, however, be influenced by other factors, as outpatient vs inpatient transplantation setting, which were not reported in our study. The benefits and potential risks of fluoroquinolone prophylaxis must be carefully assessed, especially in centers with high fluoroquinolone resistance rates among GNRs [24] .
Empiric treatment with noncarbapenem β-lactams, or even carbapenems [25] , can be inappropriate in centers with high resistance rates to these antibiotics and lead to increased mortality [2, 13] . In our study, approximately 40% of community-acquired infections were resistant to noncarbapenems and 15%-18% to carbapenems (Supplementary Tables 4 and 5) , probably due to acquisition of resistant bacteria during previous hospitalizations. This can lead to inappropriate empiric therapy. Carbapenem treatment increases the chance of providing appropriate empiric therapy, especially in southeast European countries. In centers with low rate of noncarbapenem resistance at the onset of febrile neutropenia, noncarbapenems, however, can still be a good option. Universal recommendations for empiric therapy are tricky because of significant geographical variations. Practical decisions on empiric therapy must be based on continuously updated data concerning local resistance patterns and bacteremia rates [26] . We are thus unable to recommend the specific resistance rate threshold that indicates change in the empiric therapy protocol as our study was not designed to answer this question. While the proportion of resistant bacteria was high in some centers, its impact on patient outcome can be low if GNR bacteremia is rare (Supplementary Figures 1B and 1C) .
Resistance to multiple antibiotics complicates the targeted therapy choice. Susceptibility to tigecycline, polymyxins, fosfomycin, and aminoglycosides must be promptly reported in the centers with carbapenem-resistant infections, as some bacteria were resistant to these last-resort antibiotics in our and other studies [8, 27] . Eighteen percent of carbapenem-resistant P. aeruginosa was susceptible to both cephalosporins and βL/βLIs in our study and, in contrast to carbapenem-resistant Enterobacteriaceae, can be treated with these agents, especially administered as high-dose prolonged infusion [28] . Knowledge of pathogen-specific resistance patterns can help direct appropriate empiric therapy following rapid bacterial identification by matrix-assisted laser desorption/ionizationtime of flight (MALDI-TOF), prior to susceptibility results. Carbapenem monotherapy should be appropriate on identification of non-Klebsiella pneumoniae Enterobacteriaceae, which are usually carbapenem susceptible. A carbapenem/colistin with or without aminoglycoside combination should, however, be considered for K. pneumoniae or Acinetobacter pending susceptibility results, as a significant proportion of them are carbapenem resistant. Streamlining of antibiotic therapy, of course, should be performed when susceptibilities are available.
Data on resistance rates in post-HSCT children are scarce [12, 16, 29] . Surprisingly, resistance rates were mostly similar in children and in adults in our study. This differs from the lower resistance rates in children vs adults reported in a literature review of studies published until 2011 [4] . Resistance rates in a retrospective multicenter US study (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) in pediatric allo-HSCT recipients [16] are also lower than in our study. Our data may indicate the trend toward increasing resistance in children, which emphasizes the importance of monitoring and prevention in this population. Fluoroquinolone prophylaxis is rarely provided in children, which may explain lower rates of fluoroquinolone resistance.
Information about resistance rates and risk factors in auto-HSCT patients is limited and mainly concerns fluoroquinolones [15, 30] , as bacteremia is relatively less frequent in auto-HSCT patients [31] . Certain factors predisposing to resistant infections-such as breakthrough bacteremia and prolonged neutropenia-are less frequent in auto-HSCT vs allo-HSCT patients (Table 2) . Although total resistance rates were higher in allo-HSCT patients, resistance rates in community-acquired infections were similar. These data reinforce the importance of monitoring antibiotic susceptibilities in auto-HSCT patients.
Several studies reported risk factors for cephalosporin-resistant, ESBL-producing or MDR bacteria in cancer and HSCT patients [10, 12, 13, 16, 22, 29, 32] . Only a handful describe risk factors for carbapenem-resistant infections in populations involving but not limited to transplant patients, mainly for K. pneumoniae. Distinct from other studies, we found that breakthrough on noncarbapenems does not predispose to carbapenem resistance in allo-HSCT patients [8, 14] . Noncarbapenem β-lactams and carbapenems are both recommended for empiric treatment in febrile neutropenic patients [25] , half of whom have neither microbiological nor clinical infection. Limitation of carbapenem treatment, de-escalation to a narrower-spectrum regimen following culture results, and shortening treatment duration, as recommended by European Conference on Infections in Leukaemia guidelines, will slow development of carbapenem resistance without increasing mortality [26, 33] .
Geographical differences in resistance rates are striking. In certain countries, we found higher resistance rates than those previously reported in the literature. In France, for example, 34.4% of GNRs were noncarbapenem resistant, compared with 4% third-generation cephalosporin resistance among Enterobacteriaceae cultured in hematological malignancies and post-HSCT patients during 2003-2010, which may be explained by increased resistance rates over time [5] . Information about resistance rates in each country may, of course, be skewed by local epidemiology of the participating centers, and not reflective of the situation countrywide. While carbapenem-resistant GNRs were not reported at all in some countries, approximately 40% of GNRs were carbapenem resistant in Russia and the Czech Republic, countries for which existing resistance data are very limited. GNR resistance rates to carbapenems in other studies, including HSCT patients, varied from 0% in Sweden [34] to 4.7%-5.8% in the United States [8, 35 ] to 20.9%, and even 75.9% among K. pneumoniae, in Italy [7, 11, 14, 27] . Overall, we found significantly higher resistance rates in southeast as compared with northwest Europe. This correlates with lower rates of antimicrobial resistance among the general population [36] , which is probably explained by lower consumption of systemic antibacterials in the community, as well as in veterinary medicine, in northwest Europe [37, 38] .
The multidrug resistance rate (~30%) among Enterobacteriaceae and P. aeruginosa in our study was within that reported in cancer and HSCT patients [11] [12] [13] 35] . The rate of cotrimoxazole resistance among S. maltophilia, the drug of choice for this MDR pathogen, was higher in our study (19%) compared to 4%-10% in other studies [5, 29] . Susceptibility of Acinetobacter species in cancer and transplant patients has been infrequently studied [5, 29, 39] ; XDR Acinetobacter infections were not previously reported. In our study, a third of Acinetobacter species were XDR.
We demonstrated higher mortality rates in infections caused by resistant bacteria, similar to other studies [8, 12] . Analysis of mortality risk factors is beyond the scope of this manuscript.
Our study has limitations. GNR resistance rates and patterns in our study are influenced by the epidemiology of countries with more participating centers. Antimicrobial susceptibility data were incomplete for some GNRs. Resistance rates to certain agents, such as tigecycline, could be overestimated, as susceptibility was likely checked in bacteria resistant to other treatment options, or reflecting local epidemiology. We could, however, demonstrate resistance rates to salvage treatments among their main targets, harder-to-treat pathogens. We did not assess important risk factors for resistance: history of recent residency in another country (information unavailable) and prior colonization with resistant GNRs (not all participating centers performed colonization screening).
The study has important strengths. It is the first intercontinental prospective study focusing on antimicrobial resistance of GNRs specifically in HSCT patients, including countries underrepresented in the literature (eg, Russia, Switzerland), and countries with lower resistance rates, which makes our data more applicable to large-scale HSCT centers. The large sample size enables unique resistance analysis in 2 important subgroups-that is, auto-HSCT patients and children, about whom data in the literature are very scarce. It also allows comparison of data between auto-and allo-HSCT patients and between children and adults. Contrary to many studies, we analyze risk factors for different resistance patterns and pathogens, rather than focusing on specific bacteria or mechanisms.
In conclusion, the problem of antibiotic resistance is worrying in all HSCT patients, including subgroups of children and auto-HSCT recipients. It is associated with inappropriate empiric therapy and increased mortality. Benefits of fluoroquinolone prophylaxis and the approach to empiric therapy should be reassessed and grounded in continuous monitoring of the local bacteremia rates and susceptibility data of infecting pathogens. Knowledge of pathogen-specific resistances enables early appropriate empiric therapy.
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